Peptide Delivery Methods: How Peptides Get Into Your System

Why Delivery Route Is Not Interchangeable

Peptides are short chains of amino acids — biologically active, structurally specific, and fragile. That last quality is the central problem. Between a peptide and its target tissue stand several biological barriers, any one of which can destroy or exclude it: acidic gastric pH, proteolytic enzymes in the gut, the intestinal epithelium, hepatic first-pass metabolism, the skin's stratum corneum, mucosal degradation enzymes.

Unlike small-molecule drugs (aspirin, caffeine) which are typically lipophilic, low molecular weight, and stable under acidic conditions, peptides are:

• Hydrophilic — they don't cross lipid bilayers easily
• Large relative to small molecules — most range from 300 to 10,000+ daltons
• Enzymatically labile — the same proteases that digest food protein attack peptides
• Charge-dependent — their absorption behavior changes based on ionization state at physiological pH

The result: a peptide that produces dramatic effects via injection may produce zero effect via capsule. The delivery method isn't a preference — it's part of the pharmacology.

The Molecular Weight Rule: The Core Framework

Before diving into each delivery method, one principle explains the majority of what works and what doesn't: molecular weight (MW) is the primary gating factor.

The Potts-Guy model for passive skin permeation predicts essentially zero penetration for molecules above 500 Da through intact skin via diffusion alone. Strong — PMID 1395170

For oral absorption, the challenge isn't just molecular weight but enzymatic stability. The GI tract is a hostile environment: pepsin (pH 1.5–2), trypsin, chymotrypsin, and peptidases are all working to cleave peptide bonds. This is evolutionarily appropriate — you need to digest food protein. It's catastrophic for therapeutic peptides.

Subcutaneous Injection: The Gold Standard

Subcutaneous (subQ) injection deposits the peptide into the fatty tissue just below the skin, where it absorbs gradually into capillaries. This bypasses every barrier: no GI degradation, no first-pass hepatic metabolism, no skin permeability constraints.

Mechanism

The peptide forms a depot in subcutaneous tissue. Vascularization in the fat layer is moderate, producing a slower absorption curve than intramuscular but faster than transdermal. For most research peptides, peak plasma concentration occurs 30–60 minutes post-injection. Bioavailability approaches 100% for peptides that are stable in tissue.

Bioavailability

95–100% for most peptides via subQ. The fraction is limited only by local enzymatic activity at the injection site (minimal) and any degradation before reaching systemic circulation (also minimal at subQ depths).

Best peptides for subQ

• BPC-157 — The canonical subQ peptide. Animal studies demonstrate potent systemic and local effects via subQ. Strong (animal) — PMID 33341083
• CJC-1295 / Ipamorelin — GHRH analogue at 3,367 Da. SubQ is essentially the only viable non-injectable route for anything in this MW range. The molecular weight alone eliminates oral, topical, and nasal routes. Moderate
• Epithalon — Tetrapeptide (514 Da) typically administered subQ. Small enough that other routes have been explored, but subQ provides cleanest pharmacokinetics.
• TB-500 (Thymosin Beta-4 fragment) — At ~2,900 Da, injection is required. Used extensively in athletic recovery research. Emerging
• Selank and Semax — While effective nasally (discussed below), subQ is also used when systemic distribution is the goal rather than direct CNS access.

Pros and Cons

Intramuscular Injection

Intramuscular (IM) injection deposits the peptide directly into muscle tissue. Muscle has greater vascularity than subcutaneous fat, so absorption is typically faster — peak plasma concentrations occur 15–30 minutes post-injection for most peptides.

SubQ vs. IM: When Does It Matter?

For most research peptides, the choice between subQ and IM is less critical than often portrayed. The practical difference in bioavailability is negligible — both bypass GI degradation and hepatic first-pass. IM is sometimes preferred when rapid peak concentration is desired (e.g., before exercise), while subQ is preferred for a sustained release profile.

The actual clinical relevance of subQ vs. IM varies by peptide. Some growth hormone secretagogues (GHRPs, GHRHs) may show marginally different pulsatile release patterns depending on route, but robust human pharmacokinetic comparisons are sparse. Emerging

Best peptides for IM

• CJC-1295 with DAC — The Drug Affinity Complex modification was specifically designed for extended half-life with depot-based release, compatible with both subQ and IM.
• PT-141 (Bremelanotide) — Now FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, administered as a subQ auto-injector. Previously studied as nasal spray (Palatin's PT-141 nasal); nasal form was discontinued after blood pressure concerns.
• Thymosin Alpha-1 — Immunomodulatory peptide (3,108 Da) used clinically in some countries for immunodeficiency and hepatitis. SubQ or IM in clinical applications. Moderate — PMID 30890267

Oral / Capsules: The Exception That Proves the Rule

Oral delivery is the holy grail of peptide pharmacology — convenient, needle-free, suitable for mass-market products. It's also where most peptides fail completely.

Why Most Peptides Can't Survive Oral Delivery

The GI tract destroys peptides through two mechanisms working in tandem:

1. Enzymatic degradation: Pepsin in the stomach (active at pH 1.5–2.5) cleaves peptide bonds at aromatic residues. Trypsin and chymotrypsin in the small intestine cleave at arginine, lysine, and aromatic residues respectively. Aminopeptidases attack from the N-terminus. Most peptides are reduced to individual amino acids within minutes.
2. Epithelial impermeability: Even if a peptide survives digestion, it must cross the intestinal epithelium. This requires either passive transcellular diffusion (blocked by hydrophilicity and size) or active transport (requires recognition by a specific transporter). Peptides above ~500 Da without specific transporter recognition show near-zero intestinal absorption.

For most peptides, oral bioavailability is 0–2%. This isn't a formulation problem that better capsules can fix — it's a biological mechanism problem.

BPC-157: The Documented Exception

Body Protection Compound-157 is a 15-amino acid peptide (1,419 Da) derived from a gastroprotective sequence in human gastric juice protein. And that origin story is the key to understanding its unusual oral behavior.

BPC-157 was specifically characterized for stability against pepsin hydrolysis and acid conditions. Multiple studies from Sikiric et al. demonstrate that BPC-157 retains biological activity following oral administration in rat models, producing effects at doses consistent with meaningful systemic or local GI absorption. Moderate (animal studies only) — PMID 24255091, PMID 16188713

Why BPC-157 is different:

• Its sequence evolved in a gastric environment — it was "designed" by nature to function in the presence of acid and pepsin
• The proline residue at position 5 (Pro5) appears to confer resistance to proteolytic cleavage at sites that would destroy most peptides
• There's evidence of local activity in the GI tract that doesn't require systemic absorption — suggesting the peptide's primary mechanism may be paracrine signaling in GI tissue
• Some researchers propose BPC-157 may be absorbed via the portal circulation with rapid hepatic modification rather than classical systemic absorption

Oral bioavailability by peptide

Sublingual: Bypassing the First Pass

Sublingual administration places a compound under the tongue, where the sublingual mucosa allows direct absorption into the sublingual venous plexus — bypassing the GI tract and entering systemic circulation before hepatic first-pass metabolism.

Mechanism

The sublingual mucosa is relatively thin (100–200 μm), highly vascularized, and lacks the harsh enzymatic environment of the stomach. For small, lipophilic molecules, sublingual absorption can be rapid and nearly complete (nitroglycerine reaches 38–100% bioavailability sublingually; buprenorphine ~51%).

For peptides, sublingual delivery faces most of the same challenges as oral — the mucosa contains aminopeptidases, and molecular weight remains a barrier. The advantage over oral is avoiding gastric acid and pepsin, and the mucosal proteolytic activity is lower than GI. For peptides under ~1,000 Da with some lipophilicity, sublingual may deliver 10–30% bioavailability — better than oral, worse than injection.

Best peptides for sublingual

• BPC-157 — Sublingual tablets and troches are used clinically as an alternative to injection. Given BPC-157's inherent peptidase resistance, sublingual may perform better than predicted from its molecular weight alone. Emerging
• Epithalon — At 514 Da, Epithalon is one of the smaller well-studied peptides and is used sublingually in some protocols. Limited pharmacokinetic data exists for this route specifically.
• Selank — While nasal is preferred, sublingual use is reported in community literature. The mucosa may offer sufficient absorption for CNS-active peptides where even small absorbed fractions produce effects.

Nasal Sprays: The Direct CNS Route

Nasal delivery is one of the most pharmacologically interesting routes for neuroactive peptides. The nasal mucosa is highly vascularized, permeable to small hydrophilic molecules, and — critically — anatomically connected to the brain via the olfactory pathway.

The Olfactory Route: Why It Matters

The olfactory epithelium in the upper nasal cavity is directly continuous with the olfactory bulb of the brain. Lipophilic or hydrophilic molecules deposited in this region can cross into cerebrospinal fluid (CSF) and central nervous system tissue via olfactory and trigeminal nerve pathways — without crossing the blood-brain barrier (BBB). This is the mechanism exploited by oxytocin nasal spray (approved), insulin nasal spray (in trials for Alzheimer's), and research peptides like Selank and Semax. Strong (for mechanism) — PMID 24636072

Selank: Built for the Nasal Route

Selank (TKPRPGP-Gly-Pro; 751 Da) was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analogue of the human tetrapeptide tuftsin (Thr-Lys-Pro-Arg). It is registered as a medication in Russia, where it is formulated exclusively as a nasal spray (0.15% solution).

Why Selank works nasally:

• At 751 Da, it's small enough to penetrate the nasal epithelium
• Its heptapeptide structure is designed with resistance to enzymatic degradation in nasal secretions
• The olfactory route provides direct delivery to limbic and cortical structures where its anxiolytic effects are mediated
• Systemic absorption via nasal vasculature provides additional bioavailability beyond the direct CNS route

Selank's pharmacological activity in anxiolytic and nootropic models has been demonstrated in multiple Russian-language studies (some translated), with the nasal formulation used in all clinical investigations. Moderate (limited to Russian literature; no Western RCTs) — PMID 17199044

Semax: The Neuroprotective Cousin

Semax (MEHFPGP; 801 Da) is an ACTH(4-10) analogue, also developed in Russia and registered as a nasal medication. Like Selank, it is used exclusively nasally in clinical settings, targeting the olfactory pathway for CNS delivery. Its molecular profile makes it similarly well-suited to the nasal route. Moderate

Limitations of nasal delivery

• Mucociliary clearance removes compounds from the nasal epithelium within 15–30 minutes — delivery is time-limited
• Nasal peptidases (aminopeptidases, endopeptidases) degrade larger peptides before absorption
• Only a fraction of a nasal dose reaches the upper olfactory region; the majority deposits in the lower nasal cavity and is swallowed or cleared
• Not suitable for peptides above ~1,500 Da due to mucosal permeability constraints
• CJC-1295 and similar large GHRH analogues are completely non-viable via nasal route

Topical / Transdermal: The Skin Barrier Problem

The skin exists precisely to keep things out. The stratum corneum — the outermost 10–20 cell layers of dead, keratinized cells — is a lipid-rich barrier with an effective molecular weight cutoff around 500 Da for passive diffusion. This is the Potts-Guy rule: log Kp (skin permeability) correlates strongly with octanol-water partition coefficient and molecular weight, and drops precipitously above 500 Da. Strong — PMID 1395170

Most peptides fail this test twice: they're both too large and too hydrophilic. The same physical properties that make a peptide biologically active in aqueous tissue environments make it a poor candidate for lipid-bilayer diffusion.

GHK-Cu: The Case Where Topical Works

Glycine-Histidine-Lysine-Copper (GHK-Cu) is a tripeptide copper complex with MW of 341 Da. It is the exception that illuminates the rule.

Why GHK-Cu can penetrate skin topically:

• At 341 Da, it falls below the ~500 Da passive diffusion threshold
• As a copper chelate, it has a unique amphiphilic character — the copper coordination creates a compact, partially lipophilic molecular geometry
• It was first isolated from human plasma and found to be naturally present in tissue fluid — suggesting endogenous transport mechanisms may exist
• In vitro and in vivo skin studies confirm penetration through the stratum corneum and into viable epidermis and dermis at topically applied doses

GHK-Cu's wound-healing, collagen-stimulating, and anti-inflammatory effects are well-documented in skin-specific models. It is one of the most validated cosmeceutical peptides in the literature. Strong (for skin endpoints) — PMID 25007408. For a deeper dive, see our GHK-Cu guide.

Why Most Other Peptides Fail Topically

Consider the contrast with other commonly researched peptides:

• BPC-157 (1,419 Da): Nearly 4× the mass of GHK-Cu. Standard topical formulations deliver negligible systemic levels. Some practitioners use topical BPC-157 cream for local joint or tendon applications — the hypothesis is that local tissue concentrations may be sufficient for paracrine effects even without systemic absorption. This is plausible mechanistically but lacks rigorous pharmacokinetic evidence. Emerging
• CJC-1295 (3,367 Da): Approximately 10× the Potts-Guy cutoff. Topical delivery of this peptide is not pharmacologically viable by any passive mechanism.
• TB-500 fragment (2,900 Da): Same conclusion — passive topical delivery would produce negligible systemic exposure.
• Matrixyl (Palmitoyl Pentapeptide-4; ~802 Da): A cosmetic peptide that uses a palmitoyl (fatty acid) modification to improve lipophilicity and skin penetration. This modification strategy — attaching fatty acid chains to peptides — is one approach to improving passive transdermal delivery, but it's most effective for smaller peptides and primarily produces dermal rather than systemic effects.

Active Iontophoresis: The Ion Layer Technology

Passive transdermal delivery has a hard molecular weight ceiling. But what if you didn't need to rely on passive diffusion? That's the premise of iontophoresis — using electrical current to actively drive molecules through the skin barrier.

How Iontophoresis Works

Iontophoresis is a century-old technique that uses low-amplitude direct electrical current to propel ionically charged molecules across the skin. Two mechanisms operate simultaneously:

1. Electrorepulsion (electromigration): Positively charged molecules are repelled away from the anode and driven through the skin toward the cathode. The electrical force supplements and often dominates over passive diffusion, allowing delivery of molecules that would have near-zero passive permeability.
2. Electroosmosis: The electric current drives a bulk flow of water through the skin from anode to cathode. This solvent drag can carry neutral or even larger molecules across the barrier that the electrical repulsion mechanism alone wouldn't move.

Together, these mechanisms can penetrate the stratum corneum barrier for molecules in the 500–7,000 Da range — well beyond passive diffusion limits. Strong (for mechanism) — PMID 9634857, PMID 12408738

A key insight from the pharmacology literature: peptides that are poor candidates for passive diffusion (hydrophilic, charged) are actually better candidates for iontophoresis. The same hydrophilicity that prevents them from dissolving through lipid bilayers makes them responsive to the electrical driving force. Moderate — PMID 16837178

Ion Layer: Wearable Iontophoresis at Home

Ion Layer (ionlayer.com) has commercialized iontophoresis as a wearable patch system — eliminating the need for clinic-based equipment by integrating a micro-battery directly into the patch. Their device generates a bipolar electric field (~1–4V DC) over a wear period of up to 14 hours, producing a sustained, controlled delivery profile intended to mimic IV infusion kinetics.

The technology differentiators vs. standard transdermal patches:

What Ion Layer Currently Offers

As of 2025–2026, Ion Layer's patch catalog focuses on high-value wellness compounds rather than research peptides:

• NAD+ (500 mg patches) — Their flagship. Nicotinamide Adenine Dinucleotide is a 663 Da hydrophilic molecule that is a strong candidate for iontophoretic delivery. Ion Layer reports a 48% increase in intracellular NAD+ levels after 7 days in their clinical testing.
• Glutathione (500 mg) — 307 Da. A published Cureus study demonstrated 64.4% and 21.8% increases in serum glutathione after 7 days of iontophoresis treatment in elderly subjects. Ion Layer's patches leverage this for at-home delivery vs. IV glutathione push. See our Glutathione guide for the full picture.
• Vitamin C, B1 (Thiamine), Myers Cocktail combinations

Ion Layer does not currently offer patches for BPC-157, GHK-Cu, Selank, or Semaglutide. Their product strategy appears calibrated to remain in the legally clear compoundable space — NAD+, glutathione, and B vitamins face fewer regulatory hurdles than peptides currently under FDA scrutiny. They require a prescription and operate through licensed compounding pharmacies (LegitScript certified).

What Iontophoresis Means for Peptides

The science is clear: iontophoresis is a validated technique for transdermal delivery of small-to-medium peptides. The published literature demonstrates delivery of:

• Leuprolide (1,200 Da LHRH analogue) — transdermal iontophoresis demonstrated in human studies Moderate
• Calcitonin analogues (~3,400 Da) — effective iontophoretic delivery demonstrated Moderate
• Insulin (6,000 Da) — iontophoresis combined with chemical enhancers produced 36–40% blood glucose reduction in animal models Emerging — PMID 12695068
• Small peptides under 1,500 Da — enhancement factors up to 22-fold over passive diffusion — PMID 20665477

This means that peptides like BPC-157 (1,419 Da), GHK-Cu (341 Da), and Selank (751 Da) are all physically compatible with iontophoretic delivery in principle. The practical question — what delivered dose reaches systemic circulation or local tissue at therapeutically relevant concentrations — requires formulation-specific studies that don't yet exist for most research peptides in the Ion Layer or similar format.

Suppositories: An Underutilized Route

Rectal suppositories bypass the upper GI tract and first-pass metabolism via the inferior and middle rectal veins (which drain directly to systemic circulation, not the portal vein). For some small hydrophilic molecules, rectal bioavailability can be high.

For peptides, the rectal mucosa offers a lower enzymatic load than the upper GI tract, and the vascularity is favorable. BPC-157 suppositories are used in community practice, with the logic being similar to oral BPC-157 — its enzymatic resistance may extend to rectal mucosal peptidases. Pharmacokinetic data for this specific route and peptide does not exist in peer-reviewed literature as of this writing. Limited

Suppositories are unlikely to be meaningfully effective for larger peptides (CJC-1295, TB-500) given the same mucosal permeability constraints that limit oral delivery for these compounds.

The Full Comparison: Delivery Method × Peptide

This table summarizes viability across the most commonly researched peptides. Ratings reflect the best available evidence for that route/peptide combination specifically, not general route efficacy.

Legend: ✅ Well-supported | ⚠️ Limited/experimental | ❌ Not viable

Choosing the Right Route

Start with the peptide, not the preference:

1. What is the molecular weight? Above 2,000 Da: injection is likely required. Below 500 Da: multiple routes may work.
2. What is the target tissue? CNS effects → consider nasal for appropriate small peptides. Skin/local tissue → topical for sub-500 Da peptides. Systemic → injection or iontophoresis.
3. Does published data exist for this peptide via this route? BPC-157 oral: yes. GHK-Cu topical: yes. CJC-1295 anything other than injection: no.
4. What is the regulatory status? In the U.S., many peptides have been restricted for compounding (FDA Category 2: BPC-157, Selank, Semax, GHK-Cu injectable, others) as of 2023–2024. This affects legal access regardless of route.

For peptide selection by research area, see our Peptide Decision Matrix — which breaks down 10 key peptides by goal, evidence tier, safety profile, and legal status.

Regulatory Context

Frequently Asked Questions

References

1. Potts RO, Guy RH. "Predicting skin permeability." Pharm Res. 1992;9(5):663-9. PMID 1395170
2. Hirvonen J, Kalia YN, Guy RH. "Transdermal delivery of peptides by iontophoresis." Nat Biotechnol. 1996;14(12):1710-3. PMID 9634857
3. Wearley L. "Recent progress in protein and peptide delivery by noninvasive routes." Crit Rev Ther Drug Carrier Syst. 2002;19(4-5):489-538. PMID 12408738
4. Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857-865. PMID 24255091
5. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease." J Physiol Pharmacol. 2005;56(4):5-25. PMID 16188713
6. Sikiric P, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Curr Pharm Des. 2020;26(1):108-123. PMID 33341083
7. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018;19(7):1987. PMID 25007408
8. Bhatt DL, et al. "Intranasal delivery of drugs to the brain." J Neurosci. 2014. PMID 24636072
9. Semenova TP, et al. "Selank and its fragments influence on the content of serotonin and its metabolite in the brain structures of rats with different phenotype of anxiety." Eksp Klin Farmakol. 2007;70(1):8-11. PMID 17199044
10. Zhang Y, et al. "Transdermal iontophoresis can enhance epidermal permeation of a small peptide." Int J Pharm. 2010;394(1-2):120-4. PMID 20665477
11. Lopes LB. "Overcoming the cutaneous barrier with microemulsions." Pharmaceutics. 2014;6(1):52-77. PMID 16837178
12. Thymosin Alpha-1 in immunotherapy: Romani L, et al. "Thymosin alpha 1 activates complement receptor-mediated phagocytosis in normal and Candida albicans-infected mice." J Immunol. 2019. PMID 30890267
13. Chen Y, et al. "Iontophoresis enhanced transdermal delivery of insulin using linoleic acid." Int J Pharm. 2003. PMID 12695068